Price (delayed)
$0.713
Market cap
$68.32M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.95
Enterprise value
$54.22M
Immunic, Inc. is a clinical-stage biopharmaceutical company with a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including relapsing-remitting multiple sclerosis, ulcerative colitis, Crohn's
There are no recent dividends present for IMUX.
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.